EGRX - Eagle Pharmaceuticals Inc
(NaN%)
Sell
Moderate Growth but Declining●Stock Price Very High
59%
based on last 5 year data.
Income Statement is MODERATE
Revenue Growth is 590.93%
Operating Income Growth is 51.06%
Net Income Growth is -16.24%
Earnings Per Share (EPS) Growth is -13.86%
Net Margin is 6.38%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 4.36
Debt Ratio is 0.27
Current Debt to Net Income Ratio is 0.67
Total Debt to Total Assets Ratio is 0.17
Cash Flow is MODERATE
Cash from Operations Growth is -11.59%
Capital Expenditure is High
Net Increase in Cash is Negative
Long Term Score Trend is NEGATIVE
Investment Risk is High
based on last 4 quarter data.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Eagle Pharmaceuticals Inc (EGRX) - https://www.eagleus.com/
Exchange - NASDAQ/NMS (GLOBAL MARKET)
Industry - Pharmaceutical Preparation Manufacturing
Sector - Manufacturing
CEO - Scott Tarriff
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2021 and future.
Know the Stock © 2021 and future.